Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Genmab nets DR5 antibodies, related patents
May 2015
SHARING OPTIONS:

COPENHAGEN, Denmark—Genmab A/S has announced that Genmab Holding B.V., its subsidiary, has established an agreement to purchase antibodies and related patents from iDD Biotech SAS. The preclinical antibodies are directed against emerging cancer target DR5, also known as TRAIL receptor 2. Per the agreement, Genmab will pay iDD Biotech €2.5 million up front, and future payments could include a minimum of €3.5 million to potentially €101.5 million in development and sales milestones, as well as single-digit royalties on commercialized products.
 
“We are pleased to add this exciting target and these unique DR5 antibodies to our expanding list of preclinical assets,” Dr. Jan van de Winkel, CEO of Genmab, commented in a press release. “This move provides Genmab with another opportunity to create potential next-generation antibody drugs which could lead to new ways of treating cancer.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.